Affiliation:
1. State Institutions "Research Institute of Psychiatry of the Ministry of Health of Ukraine”, Kyiv
2. Department of Mental disorders of Child and Adolescent of State institutions "Research Institute of Psychiatry of the Ministry of Health of Ukraine", Kyiv, Ukraine
Abstract
The article presents the features
of diag nosis and treatment of schizophrenia
and bipolar disorders (BD) with
early manifestation in adolescence.
Management of disorders includes the
complex use of pharmacological, psychological
treatment and special forms
of social care. The treatment program
should include the psychoeducation
of the child and his parents and the mobilization
of family support. The article
also discusses the effi cacy of atypical
antipsychotics (risperidone, aripiprazole,
olanzapine) and mood stabilizers (valproate,
lithium, lamotrigine, and carbamazepine)
based on recommendations
Food and Drug Administration (FDA)
USA, European Medicines Agency (EMA)
and the Expert Center of the Ministry
of Health of Ukraine. The obtained results
of own conducted controlled trials
on the effi cacy and safety of olanzapine
use are discussed by the authors.
Since 2010, 22 cases of olanzapine
(Zolafren®) use for adolescents with
schizophrenia spectrum disorders aged
13—17 years have been registered
in the department of mental disorders
of children and adolescents at the
Institute of Psychiatry of the Ministry
of Health of Ukraine. The period of controlled
administration for olanzapine
at a dose of 5—20 mg per day ranged
from 44 to 70 weeks. As a result of the
study were highlighted clinical situations
in which the characteristics of the
olanzapine action profi le demonstrated
its greater effi cacy compared to risperidone
and conventional antipsychotics
in adolescents.
The aim of another controlled trial
conducted by the Institute of Psychiatry
of the Ministry of Health of Ukraine
in 2015—2018 was to evaluate the
efficacy of olanzapine at a dose
of 5—20 mg per day in adolescents with
fi rst time diagnosed acute manic/mixed
episode of BD. Nine adolescents aged
from 14 to18 years old were assigned.
Olanzapine in dose 5 to 20 mg was
an eff ective medication for treatment
of acute/mixed affective episodes
in adolescents with BD and was an acceptable
alternative to conventional
antipsycho tics and risperidone treatment.
Various side eff ects were observed
in patients receiving olanzapine therapy,
the average number of side eff ects per
patient was 2.86, while the most frequent
side eff ect was weight gain.
Keywords: schizophrenia, bipolar
disorder, antipsychotic medication,
pediatric practice, children and adolescents
Publisher
Public Organization Association of Neurologists, Psychiatrists and Narcologists of Ukraine
Reference31 articles.
1. Schulz S. C., Goerke D. Schizophrenia in children and adolescents. The Medical Basis of Psychiatry / Fatemi S., Clayton P. (Eds.). New York : Springer, 2016. P. 447—456. URL: https://doi. org/10.1007/978-1-4939-2528-5_22.
2. Manning J. S. Tools to improve differential diagnosis of bipolar disorder in primary care // Primary care companion to the Journal of clinical psychiatry. 2010. Vol. 12 (Suppl 1). P. 17—22. DOI:10.4088/PCC.9064su1c.03.
3. McClellan, J., Kowatch R., Findling R. L. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder // Journal of the American Academy of Child & Adolescent Psychiatry. 2007. Vol. 46. Suppl 1. P. 107—125. DOI:10.1097/01.chi.0000242240.69678.c4.
4. Mosolov S. N., Kostyukova E. G., Ushkalova A. V. Problemyi diagnostiki i terapii bipolyarnoy depressii: ot dokazatelnyih nauchnyih issledovaniy k klini ches kim rekomendatsiyam // Biologi ches kie metodyi terapii psihi ches kih ras st roystv (dokazatelnaya meditsina — klini ches koy praktike) / pod red. prof. S. N. Mosolova. M., 2012. S. 529—553
5. Lee S., Matejkowski J. Associations between comorbid health conditions and the use of mental health services among adults with bipolar disorder // Social Work in Health Care. 2016. Vol. 55. Issue 1. P. 28—40. URL: https://doi.org/10.1080/009813 89.2015.1107016.